Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Date:5/31/2008

pathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), and anemia (29%). Twenty percent (20%) of patients experienced at least 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Additional information about Millennium is available through its website,

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
3. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
4. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... headquartered in Greenville, SC, announced today that its Glucommander™ 2.0 ... use, ages 2 - 17. Glytec,s Glucommander was the first ... intravenous use; it is the only company to ... the only company cleared to offer this technology to hospitals ...
... LAKES, N.J. and OLATHE, Kan., May 21, 2012  BD ... a leading global medical technology company, and Heart to ... teaming up for their second joint volunteer initiative to ... employees from around the world will build upon the ...
Cached Medicine Technology:Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 3
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2
... (FRG) is pleased to announce the hiring of Dr. ... Operations. Katyal will be joining them from,West Penn Hospital, ... and Past President of the Pittsburgh Radiology Society. , ... widely regarded as the preeminent cardiovascular imager in,Western Pennsylvania. ...
... VEGAS, Nov. 25 Stop and think. That is what,Las ... Golden,Rainbow are asking Las Vegas to do this World AIDS ... marking the day with a,fundraising dinner to re-launch a new ... , For the past ...
... 25 H. Paul Dorman, Chairman and Chief Executive ... that Travis E. Baugh has joined HEALTHPOINT(R), Ltd., a ... , , ... a global operations and financial executive in a variety ...
... JNJ ) is commencing today, through a new wholly-owned ... all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. (Nasdaq: ... 24, 2008, its intent to acquire Omrix. , ... offer, stockholders of Omrix will receive $25.00 in cash for each ...
... receive breast-conserving therapy and radiation do not need ... despite current American Society of Clinical Oncology (ASCO) ... recommend follow-up mammograms at between six and 12 ... study in the International Journal of Radiation ...
... Secretary of Labor Elaine L. Chao today announced the appointment ... Occupational Safety and Health (NACOSH). The committee, established under ... Secretaries of labor and health and human services on occupational ... "We appreciate the advisory committee members, willingness to ...
Cached Medicine News:Health News:Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff 2Health News:Las Vegas Charities Mark World AIDS Day by Asking Residents to 'THINK' 2Health News:Travis E. Baugh Named President, COO of HEALTHPOINT, Ltd. 2Health News:Johnson & Johnson Begins Tender Offer to Acquire Omrix 2Health News:Johnson & Johnson Begins Tender Offer to Acquire Omrix 3Health News:Mammogram most effective 12 months after radiation treatment 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 3
... Microdiathermy System features an advanced design, solid ... as well as many years of clinical ... optimum choice for the placement of discrete ... burns produce the maximum effect at the ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
... Philips SureSigns C1 compact, portable ... vital signs as well as versatile ... The C1, ideal for transport and ... user interface and provides the flexibility ...
Compact networked patient monitors for flexible care....
Medicine Products: